Multiple Sclerosis Society of Canada


Nova Scotia includes LEMTRADA® on provincial drug program for eligible patients

Nova Scotia includes LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients

- Unique treatment delivered in only two cycles one year apart -

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that the Government of Nova Scotia has added LEMTRADA® (alemtuzumab) to its PharmaCare program under Exception Status Benefits for eligible people living with relapsing-remitting multiple sclerosis (RRMS).

Nova Scotia joins a growing list of provinces, including Quebec, Saskatchewan, Manitoba, Alberta, Ontario and New Brunswick in making the unique treatment available to patients 18 years or older who meet specific criteria.

"We are very excited to see Nova Scotia offer this treatment option to help people living with relapsing-remitting MS (RRMS) manage their disease," says Ben Davis, President of the MS Society of Canada, Atlantic Division.

"Knowing that Lemtrada is now available for Nova Scotians living with RRMS is another great step forward as the province joins New Brunswick in the listing of this disease modifying therapy. Our hope is that soon all Atlantic Canadians will have access so that they can choose the option that may work best for them. The MS Society of Canada encourages those who might be considering this treatment to consult with their healthcare team."

Approved in Canada in December 2013, LEMTRADA® is indicated for the management of adult patients with RRMS, defined by clinical factors and imaging results, who have had an inadequate response to interferon beta or other disease-modifying therapies.1

I’m very pleased with the addition of Lemtrada to the drug benefit list in Nova Scotia. This is a unique treatment for relapsing-remitting MS that represents an excellent option for some patients living with more aggressive forms of the disease,” said Dr. Virender Bhan, Director of the Dalhousie Multiple Sclerosis Research Unit in Halifax.

“Lemtrada is a potent new medication which has proven itself against one of the standard injectables. In the right RRMS patient this will be a very useful therapy,” said Dr. Richard Leckey, staff neurologist at the Dalhousie MS Research Unit in Halifax.

LEMTRADA® is delivered in two annual treatment courses, with the first given over five days in year one, and the second over three days in year two. As patients require monitoring at regular intervals between treatment courses and for 48 months following the final infusion, Sanofi Genzyme provides unique, comprehensive and free patient support through its MS One to One™ program.

LEMTRADA® is a monoclonal antibody. Monoclonal antibodies are proteins which bind to a unique site (called an antigen) on cells. LEMTRADA® binds to an antigen, called CD52, which is present at high levels on certain cells of the immune system. LEMTRADA® works on the immune system so that it may not attack the nervous system as much.2 Important and complete safety information about LEMTRADA can be found at:

The Phase III study CARE MS II showed that, as a second-line treatment, LEMTRADA® is more effective than interferon beta-1a in reducing the annual relapse rate and the time to onset of sustained accumulation of disability.3

"We are thrilled to see Nova Scotia joining other provinces in seeing the transformative potential of this exciting and unique treatment for those in need of another option,” says Peter Brenders, General Manager, Canada, Sanofi Genzyme.

About MS in Canada

The Multiple Sclerosis International Federation’s 2013 Atlas of MS reported that Canada has the highest rate of MS in the world with 291 cases per 100,000 people, followed by Denmark (227), Sweden (189), Hungary (176), Cyprus (175) and the U.K. (164).4

MS is an autoimmune disease of the central nervous system which attacks myelin, the protective covering of the nerves, causing inflammation and often damaging the myelin. Myelin is necessary for the transmission of nerve impulses through nerve fibres. It is unpredictable and can cause symptoms such as extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. Its effects can be physical, emotional and financial.5

MS can occur at any age, but is usually diagnosed between the ages of 15 to 40, peak years for education, career- and family-building. MS has been diagnosed in children as young as two years old – and in far older adults. MS is three times as likely to occur in women as in men and is more common in people of northern European background.5

LEMTRADA® and Genzyme® are registered trademarks of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

- 30 -

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more


LEMTRADA® and Genzyme® are registered trademarks of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.


Media Relations
Maggie Wang Maric
Sanofi Canada
(416) 667-2955

Alyssa Acorn
Cohn & Wolfe

Judith Kays
MS Society of Canada, Atlantic Division


1 LEMTRADA® Product Monograph. Available at https://
2 LEMTRADA® Consumer Information. Available at https://
3 Coles AJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012 Nov 24;380(9856):1829-39.
Available at: Accessed on June 26, 2016.
4 Multiple Sclerosis International Federation. Atlas of MS. us/advocacy/atlas/?gclid=CNjEmKyRx80CFUwvgQodIxAN5A. Accessed June 26, 2016.
5 MS Society of Canada. Who Gets MS. Accessed June 26, 2016.

Open navigation